Loading organizations...
Pharmbio Korea Inc. develops and supplies a comprehensive range of pharmaceutical products and medical devices, targeting therapeutic areas like digestive, urinary, and circulatory systems. The company invests in robust research and development to create exclusive, high-quality medicines and innovative solutions, with a portfolio that includes prescription drugs and over-the-counter medications.
Founded in 1999 by Bong Gil Nam, who remains its Chairman and Owner, Pharmbio's inception was driven by an insight to differentiate itself within the healthcare market. This involved focusing on specialized, effective treatments designed to yield superior medical outcomes, thereby establishing a distinct and impactful presence.
Pharmbio's diverse product lines serve patients and healthcare professionals, providing essential health products globally. The company's vision is to enhance human health and quality of life through the consistent delivery of high-quality healthcare solutions. They aim to be a prominent leader in the international pharmaceutical and medical device sectors.
Pharmbio has 1 tracked investment across 1 company. The latest tracked deal is $7.1M Series A in Master Meditech in March 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 29, 2021 | Master Meditech | $7.1M Series A | — | Foresite Capital, Huons, INNOCENCE, King Mind Partners, Paratus Investment, Samho Green Investment, Springcamp |